Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267585 | 1.00 | CA1 (0.40) | CA1CA9CA12CA2GAA | |
| SCHEMBL10627311 | 0.80 | MCL1 (0.42) | CA1CA9CA12GAALMNA | |
| SCHEMBL610788 | 0.75 | CA12 (0.41) | CA1CA9CA12GAAALDH1A1 | |
| SCHEMBL6887707 | 0.74 | CA12 (0.48) | CA1CA9CA12CA2GAA | |
| SCHEMBL31653832 | 0.73 | KEAP1 (0.43) | CA1CA9CA12CA2GAA | |
| SCHEMBL317626 | 0.73 | CA12 (0.42) | CA1CA9CA12GAALMNA | |
| SCHEMBL317703 | 0.73 | KEAP1 (0.43) | CA1CA9CA12CA2GAA | |
| SCHEMBL1464604 | 0.72 | CA12 (0.41) | CA1CA9CA12GAALMNA | |
| SCHEMBL15956316 | 0.71 | ALDH1A1 (0.53) | CA9CA12CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL7720113 | 0.71 | ALDH1A1 (0.47) | CA1CA9CA12CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675480-B1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN INC (US) | 2018-12-26 | — | — | EP | claimed |
| EP-1853634-B1 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| EP-1776389-B1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-06-29 | — | — | EP | claimed |
| US-9353127-B2 | Methods of preparation of conjugates | IMMUNOGEN, INC. (US) | 2016-05-31 | — | — | US | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| EP-2675481-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| EP-2675480-A1 | METHODS OF PREPARATION OF CONJUGATES | ImmunoGen, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| US-8420802-B2 | Polymer support | UNIVERSITY OF CAPE TOWN (ZA) | 2013-04-16 | — | — | US | claimed |
| WO-2012112708-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| WO-2012112687-A1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| EP-2478049-A1 | A POLYMER SUPPORT | University of Cape Town (ZA) | 2012-07-25 | — | — | EP | claimed |
| US-20120178916-A1 | Polymer Support | UNIVERSITY OF CAPE TOWN (ZA) | 2012-07-12 | — | — | US | claimed |
| WO-2011083360-A1 | A POLYMER SUPPORT | UNIVERSITY OF CAPE TOWN (ZA) | 2011-07-14 | — | — | WO | claimed |
| US-7662629-B2 | Peptide scaffolds for transfer of molecules into eukaryotic cells | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-02-16 | — | — | US | claimed |
| EP-1441035-B1 | Method of obtaining profiles of differential protein expression | BIOVENDOR LAB MEDICINE INC (CZ) | 2005-03-23 | — | — | EP | claimed |
| EP-1441035-A1 | Method of obtaining profiles of differential protein expression | BioVendor Laboratory Medicine, Inc. (CZ) | 2004-07-28 | — | — | EP | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | IMMUNOGEN, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2001057067-A1 | LIGAND FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | SUPRATEK PHARMA INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000012114-A1 | PEPTIDE SCAFFOLDS FOR TRANSFER OF MOLECULES INTO EUKARYOTIC CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197898-A1 | SUBSTITUTED BENZO[5,6][1,4]DIAZEPINO[1,2-a]INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MKI67, GABBR1, GABBR2 | CA1 2769/4885CA9 3967/4885CA12 3665/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | CA1 4423/4885CA9 3439/4885CA12 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.